Next Article in Journal
Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer
Previous Article in Journal
Reactive Oxygen Species and Antitumor Immunity—From Surveillance to Evasion
Article

Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era?

1
Comprehensive Cancer Center, Università Cattolica del Sacro Cuore-IRCCS, 00168 Rome, Italy
2
Comprehensive Cancer Center, Policlinico Universitario “Agostino Gemelli”-IRCSS, 00168 Roma, Italy
*
Author to whom correspondence should be addressed.
These authors equally contributed to this work.
Cancers 2020, 12(7), 1749; https://doi.org/10.3390/cancers12071749
Received: 30 May 2020 / Revised: 25 June 2020 / Accepted: 29 June 2020 / Published: 1 July 2020
Background: Guidelines recommend a perioperative approach in patients with stage II/III gastric cancer, but in real-life many patients receive immediate surgery followed by adjuvant chemotherapy (aCT). Although histologic subtypes may have different response to CT, no study has explored the influence of histotype on the efficacy of perioperative CT (pCT) or aCT. Materials and methods: The objective of the study was to evaluate the impact of clinicopathological features and histology (intestinal or diffuse) on survival according to strategy (pCT vs. aCT). The primary endpoint was overall survival (OS) and the secondary endpoint was event-free survival (EFS). Results: Out of 203 patients affected by LAGC, 83 received pCT and 120 aCT. At multivariate, histology and LVI in pCT cohort and positive resection margin in the aCT influenced both OS and EFS. No difference in EFS and OS was observed in relation to strategy. However, in the intestinal-type of pCT cohort survival outcomes were significantly higher compared to the aCT cohort, whereas in the diffuse-type were significantly worse in patients receiving pCT compared to those receiving aCT. Conclusions: Although retrospective and small-sized, this study suggests that the benefit of pCT might be limited to the intestinal-type. This hypothesis needs to be confirmed in prospective series. View Full-Text
Keywords: gastric cancer; diffuse histology; intestinal histology; neo-adjuvant therapy; perioperative therapy; adjuvant therapy gastric cancer; diffuse histology; intestinal histology; neo-adjuvant therapy; perioperative therapy; adjuvant therapy
Show Figures

Figure 1

MDPI and ACS Style

Zurlo, I.V.; Basso, M.; Strippoli, A.; Calegari, M.A.; Orlandi, A.; Cassano, A.; Di Salvatore, M.; Garufi, G.; Bria, E.; Tortora, G.; Barone, C.; Pozzo, C. Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era? Cancers 2020, 12, 1749. https://doi.org/10.3390/cancers12071749

AMA Style

Zurlo IV, Basso M, Strippoli A, Calegari MA, Orlandi A, Cassano A, Di Salvatore M, Garufi G, Bria E, Tortora G, Barone C, Pozzo C. Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era? Cancers. 2020; 12(7):1749. https://doi.org/10.3390/cancers12071749

Chicago/Turabian Style

Zurlo, Ina V., Michele Basso, Antonia Strippoli, Maria A. Calegari, Armando Orlandi, Alessandra Cassano, Mariantonietta Di Salvatore, Giovanna Garufi, Emilio Bria, Giampaolo Tortora, Carlo Barone, and Carmelo Pozzo. 2020. "Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan–Cancer Analysis Era?" Cancers 12, no. 7: 1749. https://doi.org/10.3390/cancers12071749

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop